Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients ( n = 269) who underwent HCT at our center from 2010 to 2020 in complete remission (CR) after FTBI-etoposide and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2024-11, Vol.59 (11), p.1542-1551
Hauptverfasser:	Otoukesh, Salman, Yang, Dongyun, Mokhtari, Sally, Pourhassan, Hoda, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet, Aribi, Ahmed, Artz, Andrew, Aldoss, Ibrahim, Pullarkat, Vinod, Ali, Haris, Blackmon, Amanda, Becker, Pamela, Curtin, Peter, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Al Malki, Monzr M.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059 631/67/1990/283/2125 692/308/575 Adolescent Adult Aged Cell Biology Child Child, Preschool Conditioning Cyclophosphamide Disease prevention Donors Etoposide Female Fludarabine Graft vs Host Disease - mortality Graft vs Host Disease - prevention & control Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Influenza Internal Medicine Leukemia Male Medicine Medicine & Public Health Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Prophylaxis Public Health Remission Remission (Medicine) Stem cell transplantation Stem Cells Survival Transplantation Conditioning - methods Unrelated Donors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients ( n = 269) who underwent HCT at our center from 2010 to 2020 in complete remission (CR) after FTBI-etoposide and CNI-based GvHD prophylaxis for matched donor HCT (ETOP-package; n = 196) or FTBI-Fludarabine and post-transplant cyclophosphamide (PTCy)-based prophylaxis for HLA- mismatched (related or unrelated) donors (FLU-package; n = 64). Patients in FLU-package showed a significant delay in engraftment ( p
ISSN:	0268-3369 1476-5365 1476-5365
DOI:	10.1038/s41409-024-02378-0